NasdaqCM - Nasdaq Real Time Price USD

Akebia Therapeutics, Inc. (AKBA)

1.3300

-0.0400

(-2.92%)

At close: 4:00 PM EDT

1.3399

+0.01

(+0.74%)

After hours: 4:45 PM EDT

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

PR Newswire 23 days ago

AKBA
-2.92%
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e

Benzinga 28 days ago

AKBA
-2.92%
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.

Zacks 28 days ago

AKBA
-2.92%
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the phy

PR Newswire 28 days ago

AKBA
-2.92%
Akebia Awaits FDA Word On Second Crack At Vadadustat

The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included safety data from tens of thousands of patients in Japan, where vadadustat was approved in mid-2020. Akebia has said it is prepping for a U.S. commercial launch of vadadustat in the second half if it gets an FDA green light.

Barrons.com 30 days ago

AKBA
-2.92%
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

It's been a pretty great week for Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders, with its shares surging 16...

Simply Wall St. last month

AKBA
-2.92%
Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

Akebia Therapeutics ( NASDAQ:AKBA ) Full Year 2023 Results Key Financial Results Revenue: US$194.6m (down 34% from FY...

Simply Wall St. last month

AKBA
-2.92%
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

Financial Highlights and Upcoming PDUFA Date for Vadadustat

GuruFocus.com last month

AKBA
-2.92%
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

AKBA
-2.92%
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and recent business highlights. Akebia is preparing for a potential launch of vadadustat, which is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of March 27, 2024.

PR Newswire last month

AKBA
-2.92%
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024. Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act (PDUFA) target action date for vadadustat, which is under review by the U.S. Food and Drug Administration as a treatment for a

PR Newswire last month

AKBA
-2.92%
Akebia Secures $55 Million Term Loan Financing

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

PR Newswire 2 months ago

AKBA
-2.92%
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets.

PR Newswire 3 months ago

AKBA
-2.92%
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST.

PR Newswire 4 months ago

AKBA
-2.92%
Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year

It hasn't been the best quarter for Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders, since the share price has...

Simply Wall St. 4 months ago

AKBA
-2.92%
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST.

PR Newswire 5 months ago

AKBA
-2.92%
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript November 8, 2023 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.09. Operator: Good day and thank you for standing by. Welcome to the Akebia Therapeutics’ Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only […]

Insider Monkey 5 months ago

AKBA
-2.92%
Q3 2023 Akebia Therapeutics Inc Earnings Call

Q3 2023 Akebia Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

AKBA
-2.92%
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

PR Newswire 5 months ago

AKBA
-2.92%
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it originally entered into in November 2019. The amendment extends the maturity date of the loan to March of 2025 from November 11, 2024. Under the terms of the amendment, Akebia's quarterly principal pay

PR Newswire 5 months ago

AKBA
-2.92%

Performance Overview

Return	AKBA	S&P 500
YTD	+7.26%	+5.84%
1-Year	+98.21%	+22.03%
3-Year	-56.68%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Akebia Awaits FDA Word On Second Crack At Vadadustat

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Akebia Secures $55 Million Term Loan Financing

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript

Q3 2023 Akebia Therapeutics Inc Earnings Call

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

Performance Overview